Clinical trials: Age-Related Atrophy
Age-related Degenerated Disease
Relationships Between Quality of Ageing and Age-related Degenerated Disease (Compalimage)
This project aims to assess the impact of chronic micro-inflammation on age-related loss of muscle (sarcopenia) and bone (osteopenia).
- Trial name
- Compalimage (NCT00862615)
- Testing
- Measurement of muscle protein synthesis using stable isotopes and muscle biopsies.
- Where
- France
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand
Cognitive Decline, Age-Related Memory Disorders
Prehabilitation Exercise Plus Perioperative Optimization of Senior Health
The purpose of this study is the examine the feasibility of and estimate the efficacy of a preoperative exercise (i.e. prehabilitation) program in 40 up to sedentary older adults (i.e.
- Conditions
- Cognitive Decline, Age-Related Memory Disorders, Postoperative Complications, Age-Related Atrophy
- Trial name
- NCT03291795
- Testing
- Exercise Intervention
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Duke University
Dry Macular Degeneration, Geographic Atrophy
Study of Subretinal Implantation of Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry AMD
The Phase I/IIa clinical trial is designed to assess the feasibility of delivery and safety of Human Embryonic Stem Cell-Derived RPE Cells on a parylene membrane (CPCB-RPE1) in patients with advanced, dry age-related macular…
- Trial name
- NCT02590692
- Testing
- CPCB-RPE1
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- Regenerative Patch Technologies, LLC
Age Related Macular Degeneration
Carbidopa-Levodopa in Dry AMD With Geographic Atrophy
From 3 large patient databases, patients diagnosed with AMD who have never taken levodopa(L-DOPA) containing medications have a mean age of diagnosis at 71 years.
- Trial name
- NCT03451500
- Testing
- carbidopa-levodopa
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Snyder, Robert W., M.D., Ph.D., P.C.
Age-Related Macular Degeneration
Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD
The purpose of his study is to evaluate the long term safety and tolerability of MA09-hRPE cellular therapy in patients with advanced dry Age-Related Macular Degeneration (AMD) from one to five years following the surgical…
- Trial name
- NCT02463344
- Testing
- MA09-hRPE
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Astellas Institute for Regenerative Medicine
Macular Degeneration, Age-Related, Geographic Atrophy
A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
The purpose of this study is to evaluate the long-term safety and tolerability of intravitreal (ITV) injections of galegenimab (FHTR2163) administered every 4 weeks (Q4W) or every 8 weeks (Q8W) in participants with geographic…
- Trial name
- NCT04607148
- Testing
- Galegenimab
- Where
- 48 sites in United States
- Volunteers
- 144 people
- Sponsor
- Genentech, Inc.
Macular Degeneration, Macular Degeneration, Wet
Prediction of Progression of Age-Related Macular Degeneration
The goal for this study is to initiate a randomized, controlled clinical trial to test the viability of personalized AMD progression prediction models.
- Conditions
- Macular Degeneration, Macular Degeneration, Wet, Macular Degeneration, Dry
- Trial name
- NCT04640649
- Testing
- Algorithm prediction
- Volunteers
- 278 people
- Sponsor
- University of Illinois at Chicago
Muscle Weakness, Muscle Loss
Physical Activity as Intervention Against Age-related Loss of Muscle Mass and Function
A minimum of 450 healthy individuals (62-70 years old) will be recruited. Each individual will be randomized into one of three groups stratified according to gender (M/F), BMI (≤28/>28), and 30 sec chair stand (≤11/>11).
- Conditions
- Muscle Weakness, Muscle Loss, Sarcopenia, Physical Activity
- Trial name
- LISA (NCT02123641)
- Testing
- Heavy resistance training, Moderate intensity training, Control
- Where
- Denmark
- Volunteers
- 451 people, healthy volunteers welcome
- Sponsor
- Bispebjerg Hospital
Age Related Macular Degeneration (ARMD)
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD).
- Trial name
- ReNEW (NCT06373731)
- Testing
- Elamipretide
- Where
- 53 sites in United States, Czechia and 6 more
- Volunteers
- 313 people
- Sponsor
- Stealth BioTherapeutics Inc.
Geographic Atrophy Secondary to Age-related Macular Degeneration
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
A Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination with Syfovre/Pegcetacoplan (APL-2) in Patients…
- Trial name
- NCT07215390
- Testing
- APL-3007, pegcetacoplan (APL-2)
- Where
- 78 sites in United States
- Volunteers
- 240 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Visual Acuity, Geographic Atrophy
Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)
The purpose of the study is to evaluate the efficacy and safety of CNTO 2476 cells administered into the subretinal space by the suprachoroidal surgical approach and the subretinal access kit (SRAK-02) in participants with visual…
- Conditions
- Visual Acuity, Geographic Atrophy, Macular Degeneration
- Trial name
- NCT02895815
- Testing
- CNTO 2476 (6.0 * 10^4 cells), CNTO 2476 (3.0 * 10^5 cells)
- Sponsor
- Janssen Pharmaceutical K.K.
Age-related Macular Degeneration, Age-related Maculopathy
GARM II: A Study on the Genetics of Age-related Maculopathy
The original study (GARM I) has been conducted for more than 18 years at the University of Pittsburgh Medical Center (UPMC). GARM II is a nationwide research study about age-related macular degeneration in the next generation of…
- Trial name
- NCT01115387
- Testing
- Observational-1, Observational-2
- Where
- 2 sites in United States
- Volunteers
- 603 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Macular Degeneration, Age Related, Geographic Atrophy
COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy
The goal of this clinical trial is to compare measurements of geographic atrophy (GA) area between several types of imaging, in order to assess accuracy.
- Trial name
- COCO-GA (NCT05961332)
- Testing
- Spectralis FAF imaging, Optos imaging, Zeiss Clarus 700 imaging
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of Wisconsin, Madison
Age-Related Macular Degeneration, Geographic Atrophy
Personalized Monitoring of Non-foveal, Non-vision Compromising Atrophic Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression
The goal of this prospective, multinational, multicenter observational study is to assess and predict progression in non-foveal, non-vision compromising atrophic AMD on an individual-based level over two years.
- Trial name
- APENNINES (NCT06351657)
- Where
- 7 sites in Austria, France and 4 more
- Volunteers
- 200 people
- Sponsor
- Medical University of Vienna
Age-Related Atrophy
Use of AAM for Correction of Age Related Volume Deficits in the Face
The purpose of this study is to evaluate Allograft Adipose Matrix (AAM) in the face of people with age-related volume deficit - fat loss. AAM is a tissue used to correct fat loss.
- Trial name
- NCT03652844
- Testing
- AAM
- Where
- 3 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Musculoskeletal Transplant Foundation
Nonexudative Age-related Macular Degeneration
Directional Spread in Geographic Atrophy
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in industrial countries. In the late stages of the disease, neovascular changes or the development of geographic atrophy (GA) may induce severe…
- Trial name
- DSGA (NCT02051998)
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- University Hospital, Bonn
Stargardts, Retinitis Pigmentosa
High Resolution Retinal Imaging
Studying the morphology and function of the normal and diseased retina in vivo is needed for advancing the detection, diagnosis, and treatment of retinal disease.
- Conditions
- Stargardts, Retinitis Pigmentosa, Age-related Macular Degeneration, Choroideremia
- Trial name
- AOSLO (NCT01866371)
- Testing
- Retinal imaging
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Geographic Atrophy
Pterygopalatine Ganglion Stimulation for the Treatment of Geographic Atrophy
The goal of this clinical trial is to evaluate the feasibility and safety of pterygopalatine ganglion (PPG) stimulation in adults with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
- Trial name
- NCT07570355
- Testing
- Pterygopalatine ganglion stimulation
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Shanghai Institute of Acupuncture, Moxibustion and Meridian
Age-related Macular Degeneration
Evaluate the Quality of Life of Patients With AMD
Age-related macular degeneration (AMD) is a major cause of deep visual acuity loss. Because of progressive deterioration of the macula, patients with AMD complain about progressive visual problems that can impair their quality of…
- Trial name
- QUASAR (NCT03242083)
- Testing
- quality of life questionnaire
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Geographic Atrophy, Age-related Macular Degeneration
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
The main purpose of this study is to assess the ocular and systemic safety and tolerability of RO7669330 in participants with GA secondary to AMD in at least one eye in Part 1, or both eyes in Part 2, after multiple unilateral…
- Trial name
- NCT06961370
- Testing
- RO7669330, Syfovre™, Izervay™
- Where
- 17 sites in United States
- Volunteers
- 27 people
- Sponsor
- Hoffmann-La Roche